Orion Oyj — Earnings Release 2015

Apr 24, 2015

Disclosure 323813

Orion - Company Announcement

Orion upgrades full-year outlook for 2015

ORION CORPORATION STOCK EXCHANGE RELEASE 24 APRIL 2015 at 9.25 A.M. EEST Orion upgrades full-year outlook for 2015 Orion Corporation upgrades the full-year outlook estimate for 2015 provided on 4 February 2015. Operating profit of the first quarter was EUR 83 million which is 23 % higher than in the previous year. Based on the good start for the year the company estimates that the full-year operating profit will be higher than estimated previously. New full-year outlook estimate for 2015, provided on 24 April 2015 Net sales will be slightly lower than in 2014 (net sales were EUR 1,015 million in 2014). Operating profit is estimated to exceed EUR 230 million. The Group's capital expenditure will be about EUR 50 million excluding substantial corporate or product acquisitions. (The Group's capital expenditure was EUR 57 million in 2014) Previous full-year outlook estimate for 2015, provided on 4 February 2015 Net sales will be slightly lower than in 2014 (net sales were EUR 1,015 million in 2014). Operating profit is estimated to exceed EUR 200 million. The Group's capital expenditure will be about EUR 50 million excluding substantial corporate or product acquisitions. (The Group's capital expenditure was EUR 57 million in 2014) Orion will publish the Interim Report January-March 2015 on Wednesday, 29 April 2015. Orion Corporation Timo Lappalainen Olli Huotari President and CEO SVP, Corporate Functions Contact person: Jari Karlson, CFO tel. +358 10 426 2883 Publisher: Orion Corporation Communications Orionintie 1A, FI-02101 Espoo, Finland Homepage: www.orion.fi Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2014 amounted to EUR 1,015 million and the Company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ Helsinki. [HUG#1914392]